Akari Therapeutics Secures $5 Million Financing to Advance Novel ADC Platform with Spliceosome Modulator Payload
Key Insights
Akari Therapeutics raised $5 million through a registered direct offering and private placement, with significant participation from company leadership and institutional investors.
The financing supports development of the company's innovative ADC platform featuring PH1 (search), a novel spliceosome (search) modulator payload that disrupts RNA splicing in cancer cells.
Lead candidate AKTX-101 targets Trop2 (search) receptor and has demonstrated superior activity and prolonged survival compared to traditional ADCs in preclinical studies.
Akari Therapeutics has completed a $5 million financing round to advance its next-generation antibody drug conjugate (ADC) platform featuring a novel spliceosome (search) modulator payload. The December 2025 transaction included significant participation from the company's directors, officers, and executive management, alongside institutional investors.
The financing consisted of a registered direct offering of 10,043,774 American Depositary Shares (ADSs) and a concurrent private placement of pre-funded warrants for 2,563,713 ADSs, with accompanying Series G warrants. The combined purchase price was set at $0.3883 per ADS and warrant under NASDAQ at-market pricing rules.
Innovative ADC Technology Platform
Akari's differentiated approach centers on its proprietary PH1 (search) payload, a spliceosome (search) modulator designed to disrupt RNA splicing within cancer cells. This mechanism represents a departure from conventional ADC payloads that typically employ tubulin inhibitors and DNA damaging agents.
"The additional capital from this transaction supports key development initiatives for our oncology ADC payload platform, while the reduction in liabilities improves our capital structure," said Abizer Gaslightwala, Chief Executive Officer of Akari Therapeutics.
The company's lead candidate, AKTX-101, targets the Trop2 (search) receptor on cancer cells and delivers the PH1 (search) payload directly into tumors through a proprietary linker system. In preclinical animal models, the spliceosome (search) modulation has demonstrated the ability to induce cancer cell death while simultaneously activating immune cells to drive robust and durable anti-tumor activity.
Promising Preclinical Results
AKTX-101 has shown significant activity and prolonged survival relative to ADCs with traditional payloads in preclinical studies. The compound has demonstrated potential for synergy with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination with checkpoint inhibitors compared to appropriate controls.
The novel payload's mechanism of action through RNA splicing disruption offers a potentially differentiated therapeutic approach in the competitive ADC landscape. Akari's ADC discovery platform enables the generation and optimization of ADC candidates for any target of interest based on desired applications.
Debt Conversion and Capital Structure Improvement
In addition to the equity financing, existing note holders agreed to convert approximately $2.5 million of outstanding debt into pre-funded warrants for 6,409,410 ADSs and accompanying warrants at a combined exchange price of $0.4041 per ADS. This debt conversion improves the company's balance sheet while providing additional potential equity capital upon warrant exercise.
All warrants issued in the transaction carry an exercise price of $0.3883 and will be exercisable upon shareholder approval, with a five-year term from the initial exercise date.
Development Strategy and Fund Utilization
The net proceeds will support continued research and development activities, working capital, and general corporate purposes. The company plans to generate validating data on its novel PH1 (search) payload to advance its lead asset and explore additional undisclosed targets using this innovative payload technology.
Ladenburg Thalmann & Co. Inc. (search) served as the exclusive placement agent for the offering, which closed on December 17, 2025. The financing follows a previous $2.5 million registered direct offering completed in October 2025, demonstrating continued investor interest in the company's novel ADC approach.